AGON’s Post

We are honored to introduce the third group of distinguished speakers who will enrich our discussions at this landmark event. These leaders are driving innovation and transformation across healthcare, pharmaceuticals, and digital technology in the region: 1️⃣ Dr. Gamal El-Leithy Chairman & CEO, Future Pharmaceutical Industries (FPi) | Head, Pharmaceutical Chamber, Federation of Egyptian Industries – Shaping the future of pharmaceutical innovation and industry leadership. 2️⃣ Prof. Dr. Aiman S. El Khatieb Vice President, Egyptian Drug Authority – Enhancing regulatory frameworks for pharmaceutical excellence and innovation. 3️⃣ Eng. Mahmoud Badawi Advisor to the Minister on Digital Transformation Affairs, Ministry of Communications and Information Technology (MCIT), Egypt – Pioneering digital transformation in healthcare for a more connected and efficient system. 4️⃣ Dr. Hesham Badr Vice President, Egyptian Authority for Unified Procurement, Medical Supply, and Technology Management – Streamlining healthcare procurement for better access and efficiency. These speakers will explore pivotal themes, including innovations in pharmaceutical manufacturing, the impact of digital transformation on healthcare delivery, and strategies for enhancing access to medical technologies through unified procurement frameworks. 📅 Join us on December 14, 2024, for the ACCESS Health MENA Contemporary Healthcare Dialogues, where thought leaders and practitioners come together to redefine healthcare for the region. 📍 Cairo, Egypt | Livestream link in the comments #HealthcareInnovation #DigitalTransformation #PharmaceuticalLeadership #MENAHealthcare #GlobalHealthSystems

Introducing the Arab Pharma Expert's Association: A New Era in Pharmaceutical Excellence Distinguished colleagues and fellow pharmaceutical professionals, I am honored to announce the upcoming launch of the Arab Pharma Expert's Association, set for next October at the International Exhibition for Pharmaceuticals and Medical Equipment (IEPM) in Dubai. This event will mark a significant milestone in advancing pharmaceutical excellence in the Arab world. As a founder, I'm proud to introduce an organization born from a vision of unity, knowledge-sharing, and innovation in all fields of pharma and not only of specific field like other existing associations. We aim to foster collaboration, enhance professional standards, and drive technological advancements across the Arab pharmaceutical landscape. Our association will be built on four key pillars: Knowledge Exchange Regulatory Harmonization Innovation Promotion Professional Development To underscore our commitment, we'll inaugurate an advanced course in Good Manufacturing Practices (GMP). I invite all pharmaceutical scientists, regulatory experts, industry leaders, and policymakers to join us in shaping the future of Arab pharmaceuticals. Together, we can build a robust, innovative, and globally competitive sector that addresses our region's healthcare needs and contributes to global advancements. The launch next October isn't just the beginning of an organization; it's the start of a movement toward pharmaceutical excellence. Join us on this transformative journey as we elevate the Arab pharmaceutical industry to new heights. We look forward to welcoming you as members and partners and realizing our shared vision for the future of Arab pharmaceuticals. #ArabPharmaExperts #PharmaceuticalExcellence #IEPM2024

Thank you to the esteemed industry leaders and experts – Alaa Darwish, Dr Srikanth Rajagopal, Mohamed Amir, Firat Incioglu, Rina Chotai, and Hasan Kapar – for joining us at the Waldorf Astoria DIFC in Dubai for a thought-provoking roundtable discussion on "Unlocking the Market: Strategies for Pharmaceutical Pricing, Access, and Tenders in the GCC" earlier this month. The event provided a valuable platform to examine the critical role of national tenders in improving access to safe and effective medicines across the region. Experts engaged in an insightful dialogue on the current state of tender practices, delving into the evolution of these systems and their impact on the pharmaceutical industry, particularly in relation to various drug types. The conversation also focused on identifying key principles and best practices for designing a national tender system that ensures fair pricing, accessibility, and operational efficiency. Stay tuned for a report highlighting the key discussion topics and emerging trends. Discover more about Clarivate’s market-leading intelligence and transformative data technology here: https://lnkd.in/gD-vvkum #Pharmaceuticals #MarketAccess #Healthcare #Tenders #PharmaStrategy #HealthcareInnovation #Dubai

The pharmaceutical industry in Saudi Arabia is undergoing a remarkable transformation, with projections of reaching $16.8 billion by 2034. This growth reflects not just economic ambition but a comprehensive shift toward innovation, enhanced healthcare infrastructure, and a commitment to addressing pressing health challenges. As Saudi Arabia aligns its healthcare goals with Vision 2030, there’s a clear emphasis on personalised medicine, AI-driven advancements, and sustainable practices. #PharmaceuticalIndustry #HealthcareInnovation #SaudiArabia

We are excited to announce that AstraZeneca is a Silver Partner for the International eHealth Forum – Morocco 2024! The commitment is to enhance access to innovative medicines and improve patient care at this year’s event, scheduled for October 30-31, 2024, in Casablanca. As a global pharmaceutical company centered on patients, AstraZeneca strives to unlock the power of science. The teams work tirelessly to push the boundaries of science to deliver life-changing medications. By 2030, AstraZeneca aims to launch at least 15 new medicines and achieve carbon negativity, making a meaningful impact on patients, society, and the planet. Heartfelt gratitude goes to all partners for their dedication to excellence in healthcare. Together, this event will serve as a significant milestone for the future of health technologies in Morocco! Fondation Mohammed VI des Sciences et de la Santé CIES, e-Health Innovation Center International eHealth Forum – Morocco #AstraZeneca #SilverPartner #InternationalEHealthForum #Morocco2024 #HealthcareInnovation #PatientCare #Pharmaceuticals #LifeChangingMedications #Science #SustainableHealthcare #HealthTech #GlobalHealth #AccessToMedicines #FutureOfHealthcare #CarbonNegativity #HealthcareExcellence

🚨 Report out now: “HTA Collaboration in the Nordics - the Role of Real-World Evidence” On the 23rd of October, we got together to discuss the Joint Nordic HTA Bodies (JNHB) collaboration, its interplay with the HTA Regulation, and the collection and use of Real-World Data and Real-World Evidence at national level. Ehm Andersson Galijatovic (Medicinrådet) introduced us to the JNHB: its creation, purpose, common supporting documents, role distribution, and an overview of the HTA process. Building on this, Maria Eriksson (The Dental and Pharmaceutical Benefits Agency, TLV) offered insights into the use of the collaborative work in national processes, as well as the preparations and expected effects of the HTA Regulation. Offering the national HTA perspective, Christian Dehlendorff (Medicinrådet) discussed the use of RWD in Danish HTA processes. Kimmo Porkka (University of Helsinki) discussed the role of RWE in HTA/Payer national collaborative initiatives. He particularly focused on the integration of clinical data from hospital sites in HTA processes, and presented a series of important learnings from the Fin-OMOP pilot project for data interoperability. Finally, Lars Moller (Pfizer Denmark) highlighted the increasing demand across Nordic countries to obtain access to innovative medicines, particularly oncological and orphan medicines, in light of the progressive fragmentation of diseases and medicines. The panel discussion session tackled:  📑 The lack of Nordic national or joint guidelines for the use of RWE 🔗 The need for increased data transportability and data standardisation 🤝 The importance of collaboration between HTAs and health technology developers and submission of fit-for-purpose data Interested to read the full report? Then make sure to check it out on our website: https://lnkd.in/dHbVZmJe #HTA #JNHB #RWE

🌟 Expanding Pharma Horizons in KSA: Insights & Strategies 🌟 Yesterday I had the honor of moderating an engaging panel discussion at the launch of CPHI Middle East, where we explored the opportunities and challenges of establishing a local footprint in Saudi Arabia's pharmaceutical sector. A huge thank you to our esteemed panelists: 🤝 Kassem Younes, FCCA, CFE Senior Managing Director, Ankura & Chair of Professional Services Committee, AmCham Saudi 🌍 Haider Hussain , Partner MENA, Fragomen Their insights into the evolving pharmaceutical business landscape in KSA, were invaluable. Key takeaways included strategies for navigating the establishment process, attracting talent, and building strong relationships with local stakeholders. 👉 If you’re considering entering KSA or other MEA markets let’s continue the conversation and explore how we can work together to unlock the potential of the region #CPHIME #Pharma #SaudiArabia #KSA #BusinessGrowth #Networking #Pharmaceuticals #MarketEntry #CulturalSensitivity #MEA #CPHI

💡 The EU introduces changes to the assessment of medicines: EU #HTA application in evaluations will gradually start next year 🔎 Many aspects of assessing medicines are changing from the direction of the European Union (#EU) and nationally; the current year is crucial in advancing these changes. This  view became clear when Jarmo Hahl, a leading consultant at Medaffcon, interviewed Kalle Aaltonen, a Senior Specialist at the Pharmaceuticals Pricing Board (Hila), and Tuomas Oravilahti, a Chief Specialist at the Finnish Medicines Agency (Fimea).* Pan-European clinical assessments of medicines (EU HTA, Health Technology Assessment) will gradually come into force in 2025. According to Kalle Aaltonen, the experiences of implementation in 2025 will determine the direction of developments from the perspective of Finnish authorities. Each EU member state submits PICO criteria for new products to improve the HTA process  🔦 What is PICO? 🔴 P = Population, Patient, Problem: The health issue and patient group being studied   🔴 I = Intervention: The intervention or method being studied to address the health issue   🔴 C = Comparator: The method against which the studied method is compared   🔴 O = Outcomes: The health outcomes the method produces, which are to be investigated  ➡ Read the whole article here in English : https://lnkd.in/dhZq9Jqg ➡ In Finnish: https://lnkd.in/d88d7k5v 📕 📊 Medaffcon Oy provides research, expert services, and consultancy to meet the needs of the pharmaceutical industry and healthcare sector. Emma, its invite-only event, addressed the development and future prospects of assessment activities as part of the introduction and reimbursement processes for new drugs, as well as the utilisation of healthcare registry data and innovative new opportunities. *Medaffcon’s Principal Consultant, Jarmo Hahl, interviewed Kalle Aaltonen, a Senior Specialist from the Pharmaceuticals Pricing Board (Hila), and Tuomas Oravilahti, a Chief Specialist at the Finnish Medicines Agency (Fimea), about drug evaluation. The event was held on April 10, 2024 at the Espoo Museum of Modern Art EMMA. #MarketAccess #Pharma #PICO #Medaffcon #freshperspectives Finnish Medicines Agency Fimea - Lääkealan turvallisuus- ja kehittämiskeskus Fimea

After attending the amazing Health Data Forum in #Portugal, many thanks to Tiago Taveira-Gomes 🥷, Paul Nunesdea, PhD, CPF, MC and Dr Osama Elhassan, Ph.D., FIHASI for the great weekend and discussions we had about #RWE, #HTA, challenges and opportunities. Great to connect with Daniela Antunes, Mariana Canelas Pais and Shirley V Wang from Harvard Medical School to learn more about #RCTs versus #RWEs studies. #Value #based #care was a hot topic as well with the amazing Professer Filipe Costa discussing the need for more #quality #data #access to enrich #research and #RWE studies. Great to meet Hugo Pedrosa from IQVIA in #Portugal. Connecting with Sigil Scientific Enterprises, MTG Research & Development Lab, NOVA Medical School - Faculdade de Ciências Médicas and NHS Wales. Great to join Ana Clara Vieira Mendonça e Silva at an exciting session that will delve into groundbreaking #innovations and #strategies that are shaping the future of #chronic #patient #care and #healthy #aging. The main points that would be the focus of the discuss: 🎯 Leveraging #Health #Data and #Technology 🎯 #Precision #Medicine and #Genomics 🎯 #Integrated #Care #Models 🎯 Focus on #Prevention and #Wellness This reminds me of the equation: #Healthspan versus #lifespan Check this post - https://lnkd.in/d4YRezCV) 👉👉👉 ......Where next.......👉👉👉 📣 I'm thrilled and excited to be attending CPHI Middle East in #Riyadh, #Saudi #Arabia from December 10-12, 2024. This is my first time at this event, and I'm looking forward to learning more about the latest trends in the #pharmaceutical #industry in the #Middle #East and #Africa region. I am partnering with Sigil Scientific Enterprises and my mentor Prof Tiago Taveira-Gomes 🥷 As a #digital #health expert, I'm particularly interested in the following topics that will be discussed at the conference: 🛸 #Digital #transformation in the #pharmaceutical industry 🛸 The use of #artificial #intelligence (#AI) in #drug #discovery and #development 🛸 The role of #blockchain in #pharmaceutical #supply #chain management 🛸 The future of #personalized #medicine I'm also looking forward to networking with other pharma professionals and learning more about the latest products and services available in the GCC market. I'm confident that CPHI Middle East will be a valuable learning experience for me. I'm also excited to share my knowledge and expertise with other attendees. ⚔ Call to action: If you're also attending CPHI Middle East, please feel free to connect with me. I'd love to chat about the latest trends in #digital #health and #pharma #research. #CPHIMiddleEast #Pharma #DigitalHealth #AI #Blockchain #PersonalizedMedicine #SaudiArabia #CPHIME

🔒 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗦𝗮𝘂𝗱𝗶 𝗔𝗿𝗮𝗯𝗶𝗮𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁: 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀🔒 As pharmaceutical companies look to expand their global footprint, Saudi Arabia is becoming an increasingly attractive option, serving as a gateway to the Middle Eastern and North African markets. At Inbeeo, we appreciate that aligning with the Saudi Arabia’s vision2030 and navigating reimbursement pathways will be critical to successful launches in this market. 🌟 𝗩𝗶𝘀𝗶𝗼𝗻 𝟮𝟬𝟯𝟬 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁: Saudi Arabia’s Vision 2030 plan allocates significant resources to healthcare, focusing on enhancing service access, improving quality, and strengthening preventive measures. This initiative presents an opportunity for pharmaceutical companies to align their strategies with national goals regarding improving healthcare. 🏥 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀: •   𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗦𝗲𝗰𝘁𝗼𝗿: Price and registration are often sufficient for access, with individual hospitals requesting additional data. •   𝗣𝗮𝗿𝗮𝗹𝗹𝗲𝗹 𝘁𝗼 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘀𝗮𝘁𝗶𝗼𝗻: Early reimbursement and physician engagement can raise product profiles and increase uptake through patient access programmes. •   𝗠𝗶𝗻𝗶𝘀𝘁𝗿𝘆 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 (𝗠𝗼𝗛) 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: National access is granted through the engagement of the MoH stakeholders, with regional Pharmacy and Therapeutic Committees (P&TCs) evaluating clinical and economic data, leading to the inclusion of the product on the Saudi National Formulary. 📊 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀: •   𝗟𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟱: These guidelines will mandate the submission of cost and budget impact analyses, with decisions from other influential HTA bodies playing a significant role. •   𝗖𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗲𝘀𝗵𝗼𝗹𝗱𝘀: SAR 50k-75k (equating to ~£10k-15,500) will be implemented from 2025. Saudi Arabia's strategic initiatives and evolving reimbursement pathways offer a viable opportunity for broadening access to innovative treatment options. By fully understanding the objectives and mechanisms linked to vision2030, companies can navigate the complexities of the market and achieve sustainable success. Written by Katie Hill, our Senior Associate Here at Inbeeo, we can support companies with aligning and developing their launch strategies for Saudi Arabia, with further adaptation to the MENA region. Contact us today! #Pharmaceuticals #Healthcare #SaudiArabia #Vision2030 #MarketEntry #HealthcareInnovation #PharmaGrowth